96 related articles for article (PubMed ID: 1960558)
1. Factors predicting for response, time to treatment failure, and survival in women with metastatic breast cancer treated with DAVTH: a prospective Eastern Cooperative Oncology Group study.
Falkson G; Gelman R; Falkson CI; Glick J; Harris J
J Clin Oncol; 1991 Dec; 9(12):2153-61. PubMed ID: 1960558
[TBL] [Abstract][Full Text] [Related]
2. Reinduction with the same cytostatic treatment in patients with metastatic breast cancer: an Eastern Cooperative Oncology Group study.
Falkson G; Gelman R; Glick J; Falkson CI; Harris J
J Clin Oncol; 1994 Jan; 12(1):45-9. PubMed ID: 8270982
[TBL] [Abstract][Full Text] [Related]
3. Prospective evaluation of carcinoembryonic antigen levels and alternating chemotherapeutic regimens in metastatic breast cancer.
Loprinzi CL; Tormey DC; Rasmussen P; Falkson G; Davis TE; Falkson HC; Chang AY
J Clin Oncol; 1986 Jan; 4(1):46-56. PubMed ID: 3510282
[TBL] [Abstract][Full Text] [Related]
4. Induction chemotherapy of dibromodulcitol, Adriamycin, vincristine, tamoxifen, and Halotestin with methotrexate in metastatic breast cancer: an Eastern Cooperative Oncology Group Study (E1181).
Chang AY; Putt M; Pandya KJ; Harris J; Gelman R; Tormey DC; Falkson G
Am J Clin Oncol; 1998 Feb; 21(1):99-104. PubMed ID: 9499270
[TBL] [Abstract][Full Text] [Related]
5. Combination chemotherapy of advanced breast cancer. Comparison of dibromodulcitol, doxorubicin, vincristine, and fluoxymesterone to thiotepa, doxorubicin, vinblastine, and fluoxymesterone: an Eastern Cooperative Oncology Group Study.
Skeel RT; Andersen JW; Tormey DC; Benson AB; Asbury RF; Falkson G
Cancer; 1989 Oct; 64(7):1393-9. PubMed ID: 2505919
[TBL] [Abstract][Full Text] [Related]
6. Combination chemotherapy for metastatic or recurrent carcinoma of the breast--a randomized phase III trial comparing CAF versus VATH versus VATH alternating with CMFVP: Cancer and Leukemia Group B Study 8281.
Aisner J; Cirrincione C; Perloff M; Perry M; Budman D; Abrams J; Panasci L; Muss H; Citron M; Holland J
J Clin Oncol; 1995 Jun; 13(6):1443-52. PubMed ID: 7751891
[TBL] [Abstract][Full Text] [Related]
7. Comparison of chemotherapy with chemohormonal therapy as first-line therapy for metastatic, hormone-sensitive breast cancer: An Eastern Cooperative Oncology Group study.
Sledge GW; Hu P; Falkson G; Tormey D; Abeloff M
J Clin Oncol; 2000 Jan; 18(2):262-6. PubMed ID: 10637238
[TBL] [Abstract][Full Text] [Related]
8. Mitomycin and tamoxifen versus mitolactol, doxorubicin, and tamoxifen in patients with previously treated breast cancer.
Falkson G; Gelman RS; Tormey DC; Taylor SG; Falkson HC
Cancer Treat Rep; 1985; 69(7-8):755-60. PubMed ID: 4016786
[TBL] [Abstract][Full Text] [Related]
9. Metastatic breast cancer: higher versus low dose maintenance treatment when only a partial response or a no change status is obtained following doxorubicin induction treatment. An Eastern Cooperative Oncology Group study.
Falkson G; Gelman RS; Glick J; Falkson CI; Harris J
Ann Oncol; 1992 Nov; 3(9):768-70. PubMed ID: 1450067
[No Abstract] [Full Text] [Related]
10. Ten-year follow-up study of premenopausal women with metastatic breast cancer: an Eastern Cooperative Oncology Group study.
Falkson G; Holcroft C; Gelman RS; Tormey DC; Wolter JM; Cummings FJ
J Clin Oncol; 1995 Jun; 13(6):1453-8. PubMed ID: 7751892
[TBL] [Abstract][Full Text] [Related]
11. Adjuvant CMFVP versus tamoxifen versus concurrent CMFVP and tamoxifen for postmenopausal, node-positive, and estrogen receptor-positive breast cancer patients: a Southwest Oncology Group study.
Rivkin SE; Green S; Metch B; Cruz AB; Abeloff MD; Jewell WR; Costanzi JJ; Farrar WB; Minton JP; Osborne CK
J Clin Oncol; 1994 Oct; 12(10):2078-85. PubMed ID: 7931477
[TBL] [Abstract][Full Text] [Related]
12. Treatment of metastatic breast cancer in premenopausal women using CAF with or without oophorectomy: an Eastern Cooperative Oncology Group Study.
Falkson G; Gelman RS; Tormey DC; Falkson CI; Wolter JM; Cummings FJ
J Clin Oncol; 1987 Jun; 5(6):881-9. PubMed ID: 3585444
[TBL] [Abstract][Full Text] [Related]
13. Eastern Cooperative Oncology Group randomized trials of observation versus maintenance therapy for patients with metastatic breast cancer in complete remission following induction treatment.
Falkson G; Gelman RS; Pandya KJ; Osborne CK; Tormey D; Cummings FJ; Sledge GW; Abeloff MD
J Clin Oncol; 1998 May; 16(5):1669-76. PubMed ID: 9586877
[TBL] [Abstract][Full Text] [Related]
14. The role of radiotherapy in the management of operable locally advanced breast carcinoma: results of a randomized trial by the Eastern Cooperative Oncology Group.
Olson JE; Neuberg D; Pandya KJ; Richter MP; Solin LJ; Gilchrist KW; Tormey DC; Veeder M; Falkson G
Cancer; 1997 Mar; 79(6):1138-49. PubMed ID: 9070491
[TBL] [Abstract][Full Text] [Related]
15. Adjuvant therapy with a doxorubicin regimen and long-term tamoxifen in premenopausal breast cancer patients: an Eastern Cooperative Oncology Group trial.
Tormey DC; Gray R; Abeloff MD; Roseman DL; Gilchrist KW; Barylak EJ; Stott P; Falkson G
J Clin Oncol; 1992 Dec; 10(12):1848-56. PubMed ID: 1453199
[TBL] [Abstract][Full Text] [Related]
16. Prognostic significance of progesterone receptor levels in estrogen receptor-positive patients with metastatic breast cancer treated with tamoxifen: results of a prospective Southwest Oncology Group study.
Ravdin PM; Green S; Dorr TM; McGuire WL; Fabian C; Pugh RP; Carter RD; Rivkin SE; Borst JR; Belt RJ
J Clin Oncol; 1992 Aug; 10(8):1284-91. PubMed ID: 1634918
[TBL] [Abstract][Full Text] [Related]
17. Tamoxifen versus high-dose oral medroxyprogesterone acetate as initial endocrine therapy for patients with metastatic breast cancer: a Piedmont Oncology Association study.
Muss HB; Case LD; Atkins JN; Bearden JD; Cooper MR; Cruz JM; Jackson DV; O'Rourke MA; Pavy MD; Powell BL
J Clin Oncol; 1994 Aug; 12(8):1630-8. PubMed ID: 8040675
[TBL] [Abstract][Full Text] [Related]
18. Long-term results of combined-modality therapy for locally advanced breast cancer with ipsilateral supraclavicular metastases: The University of Texas M.D. Anderson Cancer Center experience.
Brito RA; Valero V; Buzdar AU; Booser DJ; Ames F; Strom E; Ross M; Theriault RL; Frye D; Kau SW; Asmar L; McNeese M; Singletary SE; Hortobagyi GN
J Clin Oncol; 2001 Feb; 19(3):628-33. PubMed ID: 11157012
[TBL] [Abstract][Full Text] [Related]
19. Response to tamoxifen and fluoxymesterone in a group of breast cancer patients with disease recurrence after cessation of adjuvant tamoxifen.
Fornander T; Rutqvist LE; Glas U
Cancer Treat Rep; 1987; 71(7-8):685-8. PubMed ID: 3300966
[TBL] [Abstract][Full Text] [Related]
20. Prognostic and predictive factors for patients with metastatic breast cancer undergoing aggressive induction therapy followed by high-dose chemotherapy with autologous stem-cell support.
Rizzieri DA; Vredenburgh JJ; Jones R; Ross M; Shpall EJ; Hussein A; Broadwater G; Berry D; Petros WP; Gilbert C; Affronti ML; Coniglio D; Rubin P; Elkordy M; Long GD; Chao NJ; Peters WP
J Clin Oncol; 1999 Oct; 17(10):3064-74. PubMed ID: 10506601
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]